Determining the origin of lethal metastases in multifocal primary prostate cancer
Grant number: 1047581 | Funding period: 2013 - 2016
New biomarkers are required to accurately predict lethal prostate cancer from benign, indolent disaese that doesn't require expensive treatment. To do this relies on finding molecular differences between disease states. Advancements in high throughput genomic technologies enables us to now probe the lethal prostate cancer genome and transcriptome and distinguish this disease state from other forms of prostate cancer.
Related publications (9)
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer
Patrick McCoy, Stefano Mangiola, Geoff Macintyre, Ryan Hutchinson, Ben Tran, Bernard Pope, Peter Georgeson, Matthew KH Hong, Natalie Kurganovs, Sebastian Lunke, Michael J Clarkson, Marek Cmero, Michael Kerger, Ryan Stuchbery, Ken Chow, Izhak Haviv, Andrew Ryan, Anthony J Costello, Niall M Corcoran, Christopher M Hovens
BACKGROUND: Recent publications have shown patients with defects in the DNA mismatch repair (MMR) pathway driven by either MSH2 or..
Inferring structural variant cancer cell fraction
Marek Cmero, Ke Yuan, Cheng Soon Ong, Jan Schröder, null PCAWG Evolution and Heterogeneity Working Group, Niall M Corcoran, Tony Papenfuss, Christopher M Hovens, Florian Markowetz, Geoff Macintyre, null PCAWG Consortium
We present SVclone, a computational method for inferring the cancer cell fraction of structural variant (SV) breakpoints from whol..
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance
Ryan J Atkins, Stanley S Stylli, Natalie Kurganovs, Stefano Mangiola, Cameron J Nowell, Thomas M Ware, Niall M Corcoran, Daniel V Brown, Andrew H Kaye, Andrew Morokoff, Rodney B Luwor, Christopher M Hovens, Theo Mantamadiotis
Glioblastoma (GBM) tumor cells exhibit drug resistance and are highly infiltrative. GBM stem cells (GSCs), which have low prolifer..
Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation
Patrick J McCoy, Anthony J Costello, Niall M Corcoran, Christopher M Hovens, Michael J Clarkson
DNA-fluorescence in situ hybridisation (DNA-FISH) allows visualisation of chromosome organisation and rearrangement. FISH probes a..
3D modelling of radical prostatectomy specimens: Developing a method to quantify tumor morphometry for prostate cancer risk prediction
Marcus C Hovens, Kevin Lo, Michael Kerger, John Pedersen, Timothy Nottle, Natalie Kurganovs, Andrew Ryan, Justin S Peters, Daniel Moon, Anthony J Costello, Niall M Corcoran, Matthew KH Hong
Prostate cancer displays a wide spectrum of clinical behaviour from biological indolence to rapidly lethal disease, but we remain ..
Comparing nodal versus bony metastatic spread using tumour phylogenies
Stefano Mangiola, Matthew KH Hong, Marek Cmero, Natalie Kurganovs, Andrew Ryan, Anthony J Costello, Niall M Corcoran, Geoff Macintyre, Christopher M Hovens
The role of lymph node metastases in distant prostate cancer dissemination and lethality is ill defined. Patients with metastases ..
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Matthew KH Hong, Geoff Macintyre, David C Wedge, Peter Van Loo, Keval Patel, Sebastian Lunke, Ludmil B Alexandrov, Clare Sloggett, Marek Cmero, Francesco Marass, Dana Tsui, Stefano Mangiola, Andrew Lonie, Haroon Naeem, Nikhil Sapre, Pramit M Phal, Natalie Kurganovs, Xiaowen Chin, Michael Kerger, Anne Y Warren
Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. However, how the subclonal diversity of tumours ..
Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Ryan Stuchbery, Natalie J Kurganovs, Patrick J Mccoy, Colleen C Nelson, Vanessa M Hayes, Niall M Corcoran, Christopher M Hovens
Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. A..
Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array
Haroon Naeem, Nicholas C Wong, Zac Chatterton, Matthew KH Hong, John S Pedersen, Niall M Corcoran, Christopher M Hovens, Geoff Macintyre
BACKGROUND: The Illumina HumanMethylation450 BeadChip (HM450K) measures the DNA methylation of 485,512 CpGs in the human genome. T..